Concizumab improves clot formation in hemophilia A under flow.
Megan P JewellZaina AshourChristine H BairdMarilyn Manco JohnsonBeth Boulden WarrenAdam R WufsusChiara PalliniMichael DockalMarianne KjalkeKeith B Neeves
Published in: Journal of thrombosis and haemostasis : JTH (2024)
TFPI inhibition by concizumab enhanced activation and aggregation of platelets and fibrin clot formation in hemophilia A to levels comparable with that of rFVIIa.